Chronic Immune Thrombocytopenia in Children: Epidemiology and Clinical Presentation

Hematology/Oncology Clinics of North America

Volumn 23, Issue 6, 2009, Pages 1223-1238

  Bennett, Carolyn M ^a   Tarantino, Michael ^b  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Bleeding; Chronic childhood immune thrombocytopenic purpura; Intracranial hemorrhage; ITP; Splenectomy

Indexed keywords

ANTIBIOTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DAPSONE; ELTROMBOPAG; IMMUNOGLOBULIN; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLIN G; PREDNISONE; RAPAMYCIN; RHESUS D ANTIBODY; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIETIN; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ANTIBODY PRODUCTION; BACTERIAL INFECTION; BEHAVIOR DISORDER; BLEEDING; BONE MARROW DEPRESSION; CELL DESTRUCTION; CHILD; CHILDHOOD DISEASE; CHILL; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FLUSHING; GENE EXPRESSION; HEMOLYTIC ANEMIA; HEPATITIS B; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IRRITABILITY; JAW DISEASE; JAW PAIN; LOW DRUG DOSE; MACROPHAGE; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NEUTROPENIA; PATHOGENESIS; PATHOPHYSIOLOGY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SPLENECTOMY; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

CHILD; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 70449673096     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.08.002     Document Type: Review

References (107)

1. Imbach P., Kuhne T., Muller D., et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 46 3 (2006) 351-356
2. Cines D.B., and McMillan R. Pathogenesis of chronic immune thrombocytopenic purpura. Curr Opin Hematol 14 5 (2007) 511-514
3. Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol Suppl 69 (2008) 3-8
4. Harrington W.J., Minnich V., Hollingsworth J.W., et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 38 1 (1951) 1-10
5. Cines D.B., and Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 346 13 (2002) 995-1008
6. Berchtold P., and Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood 81 5 (1993) 1246-1250
7. Taub J.W., Warrier I., Holtkamp C., et al. Characterization of autoantibodies against the platelet glycoprotein antigens IIb/IIIa in childhood idiopathic thrombocytopenia purpura. Am J Hematol 48 2 (1995) 104-107
8. Berchtold P., Muller D., Beardsley D., et al. International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol 96 3 (1997) 477-483
9. Semple J.W. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 16 1 (2002) 9-12
10. Semple J.W., and Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 78 10 (1991) 2619-2625
11. Ware R.E., and Howard T.A. Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura. Blood 82 7 (1993) 2137-2142
12. Garcia-Suarez J., Prieto A., Reyes E., et al. Abnormal gamma IFN and alpha TNF secretion in purified CD2+ cells from autoimmune thrombocytopenic purpura (ATP) patients: their implication in the clinical course of the disease. Am J Hematol 49 4 (1995) 271-276
13. Semple J., Milev Y., Cosgrave D., et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 87 10 (1996) 4245-4254
14. Panitsas F.P., Theodoropoulou M., Kouraklis A., et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 103 7 (2004) 2645-2647
15. Andersson J. Cytokines in idiopathic thrombocytopenic purpura (ITP). Acta Paediatr Suppl 424 (1998) 61-64
16. Olsson B., Andersson P.O., Jernas M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9 9 (2003) 1123-1124
17. Ballem P.J., Segal G.M., Stratton J.R., et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura-evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 80 1 (1987) 33-40
18. Louwes H., Zeinali Lathori O.A., Vellenga E., et al. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med 106 4 (1999) 430-434
19. Houwerzijl E.J., Blom N.R., van der Want J.J., et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 103 2 (2004) 500-506
20. Aledort L.M., Hayward C.P., Chen M.G., et al. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 76 3 (2004) 205-213
21. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371 9610 (2008) 395-403
22. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 22 (2007) 2237-2247
23. Cines D.B., Bussel J.B., Liebman H.A., et al. The ITP syndrome: pathogenic and clinical diversity. Blood 113 26 (2009) 6511-6521
24. Kuhne T., Buchanan G.R., Zimmerman S., et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 143 5 (2003) 605-608
25. Rajantie J., Zeller B., Treutiger I., et al. Vaccination associated thrombocytopenic purpura in children. Vaccine 25 10 (2007) 1838-1840
26. Black C., Kaye J.A., and Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol 55 1 (2003) 107-111
27. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88 1 (1996) 3-40
28. Lusher J.M., and Iyer R. Idiopathic thrombocytopenic purpura in children. Semin Thromb Hemost 3 3 (1977) 175-199
29. Lusher J.M., and Zuelzer W.W. Idiopathic thrombocytopenic purpura in childhood. J Pediatr 68 6 (1966) 971-979
30. Choi S.I., and McClure P.D. Idiopathic thrombocytopenic purpura in childhood. Can Med Assoc J 97 11 (1967) 562-568
31. Bolton-Maggs P.H., and Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet 350 9078 (1997) 620-623
32. Neunert C.E., Buchanan G.R., Imbach P., et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 112 10 (2008) 4003-4008
33. Blanchette V.S., and Carcao M. Childhood acute immune thrombocytopenic purpura: 20 years later. Semin Thromb Hemost 29 6 (2003) 605-617
34. Blanchette V., and Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Pediatr Clin North Am 55 2 (2008) 393-420 ix
35. Stasi R., Stipa E., Masi M., et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 98 5 (1995) 436-442
36. George J.N., and Raskob G.E. Idiopathic thrombocytopenic purpura: a concise summary of the pathophysiology and diagnosis in children and adults. Semin Hematol 35 1 Suppl 1 (1998) 5-8
37. Glanz J., France E., Xu S., et al. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Pediatrics 121 3 (2008) e506-e512
38. Jayabose S., Levendoglu-Tugal O., Ozkaynkak M.F., et al. Long-term outcome of chronic idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol 26 11 (2004) 724-726
39. Belletrutti M., Ali K., Barnard D., et al. Chronic immune thrombocytopenic-purpura in children-a survey of the Canadian experience. J Pediatr Hematol Oncol 29 2 (2007) 95-100
40. Donato H., Picon A., Martinez M., et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer 52 4 (2009) 491-496
41. Watts R.G. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the Children's Hospital of Alabama. Clin Pediatr (Phila) 43 8 (2004) 691-702
42. Lilleyman J.S. Chronic childhood idiopathic thrombocytopenic purpura. Baillieres Best Pract Res Clin Haematol 13 3 (2000) 469-483
43. Imbach P., Akatsuka J., Blanchette V., et al. Immunothrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Eur J Pediatr 154 9 Suppl 4 (1995) S60-S64
44. Kuhne T. Investigation and management of newly diagnosed childhood idiopathic thrombocytopenic purpura: problems and proposed solutions. J Pediatr Hematol Oncol 25 Suppl 1 (2003) S24-S27
45. Zeller B., Rajantie J., Hedlund-Treutiger I., et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr 94 2 (2005) 178-184
46. Butros L.J., and Bussel J.B. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol 25 8 (2003) 660-664
47. Kalpatthi R., and Bussel J.B. Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. Curr Opin Pediatr 20 1 (2008) 8-16
48. Ziakas P.D., Giannouli S., Zintzaras E., et al. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 64 9 (2005) 1366-1369
49. Hazzan R., Mukamel M., Yacobovich J., et al. Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura. Pediatr Blood Cancer 47 Suppl 5 (2006) 657-659
50. Arnal C., Piette J.C., Leone J., et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29 1 (2002) 75-83
51. Liebman H.A., and Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol 14 5 (2007) 557-573
52. Heeney M.M., Zimmerman S.A., and Ware R.E. Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr 143 5 (2003) 662-665
53. Michel M., Chanet V., Galicier L., et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 83 4 (2004) 254-263
54. Wang J., and Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 25 1 (2005) 57-62
55. Blouin P., Landman-Parker J., Thuret I., et al. Evans syndrome: a retrospective study from the SHIP (French Society of Pediatric Hematology and Immunology). Blood 100 11 (2002) 3810
56. Norton A., and Roberts I. Management of Evans syndrome. Br J Haematol 132 2 (2006) 125-137
57. Wang W.C. Evans syndrome in childhood: pathophysiology, clinical course, and treatment. Am J Pediatr Hematol Oncol 10 4 (1988) 330-338
58. Cines D.B., Liebman H., and Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 46 1 (2009) S2-S14
59. Teachey D.T., Manno C.S., Axsom K.M., et al. Unmasking Evans syndrome: T cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 105 6 (2005) 2443-2448
60. Bennett C.M., Rogers Z.R., Kinnamon D.D., et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107 7 (2006) 2639-2642
61. Rao V.K., and Straus S.E. Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology 11 1 (2006) 15-23
62. Holzelova E., Vonarbourg C., Stolzenberg M.C., et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med 351 14 (2004) 1409-1418
63. Hundt M., Posovszky C., and Schmidt R.E. A new disorder of lymphocyte apoptosis: combination of autoimmunity, infectious lymphadenopathy, double negative T cells, and impaired activation-induced cell death. Immunobiology 206 5 (2002) 514-518
64. Rao V.K., Dugan F., Dale J.K., et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 129 4 (2005) 534-538
65. Teachey D.T., Greiner R., Seif A., et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 145 1 (2009) 101-106
66. Althaus K., and Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 35 2 (2009) 189-203
67. Provan D., Newland A., Norfolk D., et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120 4 (2003) 574-596
68. George J.N., Woolf S.H., and Raskob G.E. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med 30 1 (1998) 38-44
69. Blanchette V., Imbach P., Andrew M., et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344 8924 (1994) 703-707
70. Jayabose S., Patel P., Inamdar S., et al. Use of intravenous methylprednisolone in acute idiopathic thrombocytopenic purpura. Am J Pediatr Hematol Oncol 9 2 (1987) 133-135
71. Imbach P., d'Apuzzo V., Hirt A., et al. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 317 8232 (1981) 1228-1231
72. Bussel J.B. The use of intravenous gamma-globulin in idiopathic thrombocytopenic purpura. Clin Immunol Immunopathol 53 2 (1989) S147-S155
73. Beck C.E., Nathan P.C., Parkin P.C., et al. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr 147 4 (2005) 521-527
74. Blanchette V.S., Luke B., Andrew M., et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 123 6 (1993) 989-995
75. Scaradavou A., Woo B., Woloski B.M., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 89 8 (1997) 2689-2700
76. Tarantino M.D., Young G., Bertolone S.J., et al. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 148 4 (2006) 489-494
77. Gaines A.R. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 106 5 (2005) 1532-1537
78. Meyer O., Kiesewetter H., Hermsen M., et al. Efficacy and safety of anti-D given by subcutaneous injection to patients with autoimmune thrombocytopenia. Eur J Haematol 73 1 (2004) 71-72
79. Kuhne T., Blanchette V., Buchanan G.R., et al. Splenectomy in children with idiopathic thrombocytopenic purpura: a prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatr Blood Cancer 49 6 (2007) 829-834
80. Aronis S., Platokouki H., Avgeri M., et al. Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr 93 5 (2004) 638-642
81. El-Alfy M.S., El-Tawil M.M., and Shahein N. 5-to 16-year follow-up following splenectomy in chronic immune thrombocytopenic purpura in children. Acta Haematol 110 1 (2003) 20-24
82. Mantadakis E., and Buchanan G.R. Elective splenectomy in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 22 2 (2000) 148-153
83. Milen M. Critical issues concerning splenectomy for chronic idiopathic thrombocytopenic purpura in childhood. Pediatr Blood Cancer 47 Suppl 5 (2006) 734-736
84. Ramenghi U., Amendola G., Farinasso L., et al. Splenectomy in children with chronic ITP: long-term efficacy and relation between its outcome and responses to previous treatments. Pediatr Blood Cancer 47 Suppl 5 (2006) 742-745
85. Eden O.B., and Lilleyman J.S. Guidelines for management of idiopathic thrombocytopenic purpura. Arch Dis Child 67 8 (1992) 1056-1058
86. Stasi R., Pagano A., Stipa E., et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 4 (2001) 952-957
87. Giagounidis A.A., Anhuf J., Schneider P., et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 69 2 (2002) 95-100
88. Zaja F., Iacona I., Masolini P., et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 87 2 (2002) 189-195
89. Arnold D.M., Dentali F., Crowther M.A., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146 1 (2007) 25-33
90. Wang J., Wiley J.M., Luddy R., et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 146 2 (2005) 217-221
91. Mueller B.U., Bennett C.M., Feldman H.A., et al. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer 52 2 (2009) 259-262
92. Ram R., Ben-Bassat I., Shpilberg O., et al. The late adverse events of rituximab therapy-rare but there!. Leuk Lymphoma 50 7 (2009) 1083-1095
93. Carson K.R., Evens A.M., Richey E.A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113 20 (2009) 4834-4840
94. Hilgartner M.W., Lanzkowsky P., and Smith C.H. The use of azathioprine in refractory idiopathic thrombocytopenic purpura in children. Acta Paediatr Scand 59 4 (1970) 409-415
95. Quiquandon I., Fenaux P., Caulier M.T., et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 74 2 (1990) 223-228
96. Gurwitz D., Rodriguez-Antona C., Payne K., et al. Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet 17 8 (2009) 991-998
97. Hou M., Peng J., Shi Y., et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 70 6 (2003) 353-357
98. Kotb R., Pinganaud C., Trichet C., et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol 75 1 (2005) 60-64
99. Provan D., Moss A.J., Newland A.C., et al. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 81 1 (2006) 19-25
100. Zhang W.G., Ji L., Cao X.M., et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin 26 5 (2005) 598-602
101. Hicsonmez G., and Ozsoylu S. Vincristine for treatment of chronic thrombocytopenia in children. N Engl J Med 296 8 (1977) 454-455
102. Williams J.A., and Boxer L.A. Combination therapy for refractory idiopathic thrombocytopenic purpura in adolescents. J Pediatr Hematol Oncol 25 3 (2003) 232-235
103. Zver S., Zupan I.P., and Cernelc P. Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure. Int J Hematol 83 3 (2006) 238-242
104. Damodar S., Viswabandya A., George B., et al. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults-a report on 90 patients. Eur J Haematol 75 4 (2005) 328-331
105. Nurden A.T., Viallard J.F., and Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet 373 9674 (2009) 1562-1569
106. Bussel J.B., Provan D., Shamsi T., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373 9664 (2009) 641-648
107. Bussel J.B., Kuter D.J., Pullarkat V., et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113 10 (2009) 2161-2171